IP
IndiaPulse

BALAMINES

Micro Cap

Balaji Amines Limited

Industrials

Balaji Amines is a pioneer and India's largest manufacturer of aliphatic amines and methylamines, leveraging indigenous technology. It offers 40+ products across amines, derivatives, and specialty chemicals, serving 50+ countries. With an installed capacity of 2,92,000 MTPA, the company focuses on value-added products and forward integration.

₹2,242.1
+151.20 · +7.23%
Quote09 Jun, 12:00 am
Fundamentals08 Jun 2026 · screener
Score08 Jun, 11:00 pm · v4.2-nightly
Tags02 May 2026
Data confidence
Fresh enough for analysis
Investor decision lenses

One read, four checks

75+ is strong, 60-74 is usable, 45-59 is mixed, and below 45 needs caution. These are research lenses, not buy/sell instructions.

Weak fundamentals, management trust is acceptable, price trend is neutral, and recent execution is weak.

Suggested next step
Check latest quarters
Result consistency is weak; verify whether the thesis is improving or deteriorating.
U-Score
OVERVALUED
24

Fundamental lens: valuation, quality, growth, balance sheet, and cash flow.

Trust
Mixed Trust
66

low confidence · 0/0 claims checked

Technical
Neutral
56

Timing lens: price trend and sector relative strength.

Result consistency
weak
15

Rolling lens: recent quarterly delivery, not the latest single-result score.

Latest result

Quarter ended 31 Mar 2026

Excellent · 90/100

Rev +12% YoY · PAT +63% YoY · margin expansion · +19% QoQ · operating leverage

Filed 13 May 2026
Open results browser →
MetricThis quarterYoYQoQ
Revenue₹395 Cr+11.9%+19.3%
EBITDA₹94 Cr+56.7%+64.9%
Operating margin24.0%+700 bps+700 bps
PAT₹65 Cr+62.5%+109.7%
PAT margin16.5%+513 bps+709 bps

NDF means not disclosed in the current structured filing feed. It is intentionally not treated as zero.

Business and thesis

Where growth can come from, and what can break the case

Thesis intactReviewed 2026-06-08T07:39:50.429Z
Management commentary snapshot

Balaji Amines reported strong Q4FY26 consolidated results with revenue at ₹403 Cr (+19.9% QoQ, +11.7% YoY), EBITDA at ₹102 Cr (+65.3% QoQ, +51.3% YoY), and PAT at ₹65 Cr (+108.3% QoQ, +63.3% YoY). Margins expanded significantly, with EBITDA margin at 25% and PAT margin at 16%.

The company delivered robust Q4FY26 results with significant sequential and annual growth in revenue, EBITDA, and PAT, driven by stable volumes and margin expansion. Multiple new projects are nearing commissioning, indicating future growth potential and capacity utilization ramp-up, supporting the investment thesis.

Current business mix

Revenue by Geography (FY26)

Latest issuer-disclosed distribution across 2 reported categories.

Businessmix
Domestic86.8%
Exports13.2%
Growth engines

New Product & Capacity Expansions

Multiple new projects like DME, NMM, ACN, HCN, NaCN, EDTA, and EDA-based products are under execution or nearing commissioning, significantly expanding product portfolio and capacity.

Electronic Grade Chemicals for EV Batteries

The company is equipping to make Electronic Grade DMC, NMP, and TEA to cater to new age industries such as EV Batteries, positioning itself as a frontrunner.

Increased Methylamines Capacity

Methylamines capacity increased from 48,000 TPA to 88,000 TPA, with 80% captively used, providing a cost advantage and supporting value-added derivatives.

Vertical and Horizontal Integration

Integration enables maintaining a dominant position, cost competitiveness, and product switching flexibility, enhancing operational resilience.

Capacity and execution

Dimethyl Ether (DME) Plant

1,00,000 TPA capacity, expected to be commissioned during First Quarter of FY 2026-27.

N-Methyl Morpholine (NMM) Plant

5,000 TPA capacity, under execution and expected to be commissioned during FY 2026-27.

Acetonitrile (ACN) Plant

New improved process ACN plant, adding 9,000 TPA (total 18,000 TPA), expected to be commissioned during the Second Quarter of FY 2026-27.

Balaji Speciality Chemicals (BSCL) Expansion

₹750 Cr investment for products like HCN (10,000 TPA), NaCN (12,000 TPA), EDTA/EDTA-2Na (5,000 TPA) by Q4 FY26-27, and EDA-based products by H1 FY26-27.

Tailwinds

Amines Market Growth

The Amines Market is projected to grow at a CAGR of 7.8% from 2026 to 2030, expected to reach US$23.5 billion by 2030.

Strong Demand from End-User Industries

Globally, ~61% of aliphatic amines are consumed in the pharmaceutical sector and 26% in the agrochemicals industry, with significant demand for methylamines and PVP K-30 in India.

Emerging EV Battery Industry Demand

New age industries such as EV Batteries are driving demand for electronic grade chemicals like DMC, NMP, and TEA.

Import Substitution Opportunity

Balaji Speciality Chemicals manufactures import substitute products like Ethylene Diamine (EDA), Piperazine Anhydrous (PIP), and Di Ethylene Tri Amine (DETA).

Headwinds

Raw Material Sourcing Dependency

Methanol is a critical raw material primarily imported, making consistent supplies key for the industry.

Risk radar

Project Execution and Commissioning Delays

Multiple large-scale projects are under execution, and any delays in commissioning could impact revenue ramp-up and financial projections.

Commodity Price Volatility

Q4FY26 performance was supported by stable commodity prices; fluctuations in raw material or product prices could impact margins.

Management accountability

What management said, and what results must prove

Issuer guidance and extracted claims are tracked against later reported outcomes. Treat these as management statements, not IndiaPulse forecasts.

Analyst reading lens
Compare BOTH

QoQ comparison highlights strong sequential operational performance and margin recovery, while YoY comparison shows sustained growth and volume stability despite potential seasonality in the chemicals sector. New project commissioning timelines also emphasize sequential progress.

Sector KPIs management disclosed

Revenue from Operations

Revenue from Operations for Q4FY26 stood at ₹ 403 crore, as compared to ₹ 336 crore in Q3FY26 and ₹ 361 crore in Q4FY25.

EBITDA

EBITDA for Q4FY26 was ₹ 102 crore, as compared to ₹ 62 crore in Q3FY26 and ₹ 68 crore in Q4FY25.

PAT

PAT for Q4FY26 was ₹ 65 crore as compared to ₹ 31 crore in Q3FY26 and ₹ 40 crore in Q4FY25.

EBITDA Margin

EBITDA margin for Q4FY26 stood at 25 % as against 18 % in Q3FY26 and 19 % in Q4FY25.

Management forward view

Funding of New Projects

All new projects would be completed as planned with internal accruals, demonstrating financial discipline.

Strategic Focus on Value-Added Products

Management aims to move up the value-chain by focusing on high-value derivatives and specialty chemicals, targeting fast-growing industries and products with limited competition.

Cost Advantage from New Methyl Amines Plant

The Methyl Amines plant with latest technology at Unit IV, commissioned in Nov 2024, is expected to provide a cost advantage over competitors.

Long-term Benefits from Solar Power Plant

The full integration of the solar power plant is expected to yield substantial long-term benefits, reinforcing the company's position as environmentally responsible.

Thesis monitor

Numbers and claims to verify in the next filings

CheckpointCurrent evidenceWhat to verify next
Dimethyl Ether (DME) Plant CommissioningUnder erection.Commissioning in Q1 FY26-27 and subsequent utilization ramp-up.
BSCL Unit-I (EDA-based products) CommissioningAdditional reactor under execution.Commissioning by September 2026 and contribution to value-added product sales.
BSCL Unit-II (HCN, NaCN, EDTA) CommissioningErection and installation of equipment in progress.Commissioning by end of FY 2026-27 and market acceptance of new products.
Acetonitrile (ACN) Plant CommissioningImproved process based new ACN plant under execution.Commissioning during Q2 FY26-27 and impact on cost economics and production grades.

Verification checkpoints are IndiaPulse research interpretation, not investment advice.

Technical timing lens

Trend score and candlestick chart

56Neutral

SMA20 +57.7% / mo · near 52W high

Stock trend: 60
Sector RS: 51
Sector 3M: +0.4% vs Nifty +0.1%

Technical chart

BALAMINESdaily · 1Y+73.5%
Latest close ₹2242.10 on 2026-06-09
Bar
+6.3%
RSI
76
MACD hist
18.75
52W pos
98%
Hover for OHLC, volume, and indicators. Use range buttons above the chart to zoom.
₹903₹1.3k₹1.6k₹2.0k₹2.3k52H52L2025-122026-03Vol2025-112026-012026-022026-042026-06
Up bar
Down bar
Volume
Result date
SMA 50
RSI(14)

Technical trend read

Mixed signals

Signals are conflicting — long-term trend unclear. RSI 76. Wait for confirmation.

  • SMA20 rising (~29.5% over last month) — short-term momentum positive.
  • RSI(14) at 76 — overbought zone; risk of mean reversion.
  • MACD above signal, histogram expanding — bullish momentum building.
  • Within 3% of 52-week high — testing resistance.

Mechanical read from the price + indicator series above. Not a recommendation — technical setups can reverse without warning, especially around earnings and macro events.

Deep research

Valuation, score drivers, trust methodology, financials, and peers

Use these sections after reviewing the decision summary, latest result, thesis, management accountability, and technical timing above.

24U-SCORE
OVERVALUED

Fundamental score breakdown

OVERVALUED
Valuation2/30
Growth3/25
Quality0/20
Balance Sheet11/15
Cash Flow4/10
Piotroski
7/9 (+5)
Penalties
-1
Raw sum
24

Why this score?

Top U-Score contributors and drags from the latest stored fundamentals.

24/100 · OVERVALUED

Positive drivers

  • Piotroski is strong at 7/9.
  • Balance sheet contributes 11/15 to the score.
  • Cash flow contributes 4/10 to the score.

Main drags

  • Penalty bucket subtracts 1 points.
  • Fair-value margin of safety is negative at -816.7%.
  • Quality is weaker at 0/20; verify the latest quarterly trend.
Sector valuation model

Cyclical valuation: normalized earnings, not just trailing PE

Cyclical companies can look cheapest near peak profits, so IndiaPulse flags value-trap risk separately.

Cyclical normalized
Primary lens
Mid-cycle PE/EV/EBITDA using multi-year average margins or earnings.
Secondary checks
Current margin versus 5-year average, balance sheet strength, commodity cycle.
Main risk check
A low trailing PE may mean peak-cycle earnings, not true cheapness.
PE
40.5
PB
3.4
EV/EBITDA
21.5
ROE
8.8%
ROCE
11.0%
FCF Yield
Debt/Equity
0.1
MoS
-816.7%
Cyclical/value-trap warning
This sector can look cheap when profits are temporarily high. Check mid-cycle margins/earnings before relying on trailing PE.
Score movement

Stored run vs live recompute

This shows the stored score trend when snapshots exist, and also compares the latest stored nightly score with a live recompute from current fundamentals and price.

Stored run: 08 Jun 2026
v4.2-nightly
Final score
24
Previous: 24
Verdict
OVERVALUED
Previous: OVERVALUED
Margin of safety
-816.7%
Previous: -757.8%

Score history

12 stored score snapshots. Latest stored move: +0 points.

08 Jun 2026
v4.2-nightly
24
24
26
26
24
24
24
24
24
24
24
24

Factor attribution

No pillar movement versus the latest stored run. Historical score trend will appear after snapshot storage is enabled.
Trust Score
66Mixed Trust · low confidenceTrust Lite

Trust asks: does management behaviour match later outcomes? Higher is better, but confidence and evidence depth matter as much as the number.

Mixed Trust: Claim history is still being built. It ranks around the 49th percentile of the scored universe and 45th percentile within Industrials. Main check: results consistency is weak at 15/100.

Healthy Trust Lite: Promoter pledge is zero. Key concern: 3 recent quarters had PAT decline worse than 25% YoY.

Computed 22 May 2026
trust-lite-v1
0 docs indexed · 0 concall links
Score band
Mixed Trust

Usable, but needs evidence. Treat guidance with a margin of safety.

Relative rank
49th percentile

overall median 67 · Industrials: 45th pctile, median 68 · Micro: 33rd pctile, median 71

Evidence depth
Financial-only

0 documents indexed, but claim history is not strong enough yet.

Claim delivery
Outcome history still building

0 claims extracted · No contradicted claim yet

How to read this Trust Score

Mixed Trust · low confidence
What it measures
Reliability of management and financial delivery, using financial behaviour only.
Confidence
Treat this as an early read until more concalls and outcomes are matched.
Investor use
Acceptable, but check the weakest sub-score before increasing exposure.

Read Trust alongside U-Score, result consistency, and technical trend. A cheap stock with weak Trust needs a larger margin of safety; a high Trust score does not make an expensive stock attractive by itself.

Forensic breakdown

Read low sub-scores as due-diligence warnings, not automatic sell signals.

Promoter
78
strong · holding, pledge, alignment
Cash flow
67
acceptable · profit to cash conversion
Balance sheet
96
strong · leverage and solvency
Discipline
60
acceptable · capital discipline
Results
15
weak · quarterly consistency

Trust positives

  • Promoter pledge is zero.
  • 10 years of positive FCF.
  • Debt/equity is 0.07.

Trust risks

  • 3 recent quarters had PAT decline worse than 25% YoY.
  • 2/8 recent quarters had positive YoY revenue growth.
  • 2/8 recent quarters had positive YoY PAT growth.

Trust Lite uses financial behaviour only. Prefer claim-tested Trust when enough concall claims have later outcomes.

Intrinsic value

Graham Number
₹841.55
-166.4% MoS
DCF Fair PE
4.7
DCF Fair Value
₹244.58
-816.7% MoS
PEG

Fundamentals

Valuation

P/E
40.50
P/B
3.43
EV/EBITDA
21.52
Market Cap
6775.00Cr

Profitability

ROE
8.75%
ROCE
11.00%
ROA
6.16%
Dividend Y
0.53%

Growth (CAGR)

Revenue 5Y
2.00%
EPS 5Y
-7.00%
Revenue 3Y
-15.00%
EPS 3Y
-20.00%

Balance Sheet

Debt/Equity
0.07
Interest Coverage
53.00×
Altman Z
6.55
Book Value
610.00

Cash Flow

FCF Yield
FCF Positive Y
10/5
OCF
184.00 Cr
EPS TTM
51.60

Shareholding

Promoter Hold
54.59%
Promoter Pledge
0.00%
Momentum 52W
92%

Financial History

Updated 9/6/2026

Revenue

₹ Cr
No data

Net Profit

₹ Cr
No data

Return on Equity

%
No data
Verify on:NSE India ↗
All information is for study purposes only. For investment decisions, consult your financial advisor. See Playbook for methodology.